| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 11/24/2005 | CA2567301A1 Therapeutic, prophylactic and diagnostic agents for hepatitis b |
| 11/24/2005 | CA2566877A1 Medicinal composition and therapeutic method |
| 11/24/2005 | CA2566703A1 Methods of inhibiting proinflammatory cytokine expression using ghrelin |
| 11/24/2005 | CA2566677A1 Combination therapy for treating hepatitis virus infection |
| 11/24/2005 | CA2566619A1 Compositions comprising addl receptor syngap |
| 11/24/2005 | CA2566415A1 Methods and compositions for the dietary management of autoimmune disorders |
| 11/24/2005 | CA2566364A1 Hydrogel interferon formulations |
| 11/24/2005 | CA2566292A1 Mucin3 egf-like domains |
| 11/24/2005 | CA2565872A1 T-cell death-inducing epitopes |
| 11/24/2005 | CA2565407A1 Compounds for enzyme inhibition |
| 11/24/2005 | CA2565368A1 Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases |
| 11/24/2005 | CA2565154A1 Compositions for affecting weight loss |
| 11/24/2005 | CA2565084A1 Use of sulglicotide for the treatement of mucositis |
| 11/24/2005 | CA2565051A1 Novel use of peptide compounds for treating dyskinesia |
| 11/24/2005 | CA2564126A1 Method of inducing immunity against stratum corneum chymotrytic enzyme |
| 11/24/2005 | CA2563704A1 Methods and compositions for treatment of preeclampsia |
| 11/24/2005 | CA2563671A1 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 11/24/2005 | CA2562729A1 Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
| 11/24/2005 | CA2562715A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| 11/24/2005 | CA2562576A1 Cyclopeptide derivatives with anti-integrin activity |
| 11/24/2005 | CA2562283A1 Methods, compositions, and preparations for delivery of immune response modifiers |
| 11/24/2005 | CA2560981A1 Polymer-based sustained release device |
| 11/24/2005 | CA2560103A1 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 11/24/2005 | CA2508065A1 Antiproliferative drug and delivery device |
| 11/23/2005 | EP1598424A1 Paramyxovirus vector encoding ribozyme and utilization thereof |
| 11/23/2005 | EP1598422A2 Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants |
| 11/23/2005 | EP1598420A2 Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases |
| 11/23/2005 | EP1598370A2 Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions |
| 11/23/2005 | EP1598365A1 Protection of endogenous therapeutic peptides |
| 11/23/2005 | EP1598364A1 Chimerical soluble hyper IL-11 receptor and use thereof |
| 11/23/2005 | EP1598362A2 Chlamidya trachomatis antigens |
| 11/23/2005 | EP1598077A1 Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle |
| 11/23/2005 | EP1598076A1 Interleukin 6 production inhibitor |
| 11/23/2005 | EP1598075A1 Process for the isolation and / or purification of proteins |
| 11/23/2005 | EP1598074A1 Stabilized preparation containing protein |
| 11/23/2005 | EP1598057A1 Combination of acid protease enzymes and acidic buffers and uses thereof |
| 11/23/2005 | EP1597589A2 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f) |
| 11/23/2005 | EP1597587A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 11/23/2005 | EP1597585A2 Method for selecting a candidate drug compound |
| 11/23/2005 | EP1597582A2 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3) |
| 11/23/2005 | EP1597581A1 Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 4 (edg4) |
| 11/23/2005 | EP1597386A1 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
| 11/23/2005 | EP1597385A1 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1) |
| 11/23/2005 | EP1597381A2 Production of modified glycoproteins having multiple antennary structures |
| 11/23/2005 | EP1597370A1 Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
| 11/23/2005 | EP1597366A1 Modulation of insulin like growth factor i receptor expression |
| 11/23/2005 | EP1597365A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer |
| 11/23/2005 | EP1597360A2 Antiplasmin cleaving enzyme |
| 11/23/2005 | EP1597356A2 Cultured cd14+ antigen presenting cells |
| 11/23/2005 | EP1597355A2 Method and materials relating to neurogenesis |
| 11/23/2005 | EP1597349A2 Methods of screening for trpm5 modulators |
| 11/23/2005 | EP1597348A2 Conserved and specific streptococcal genomes |
| 11/23/2005 | EP1597279A1 Peptide inhibitors of thrombin as potent anticoagulants |
| 11/23/2005 | EP1597278A2 Polyethylene glycol modified interferon compositions and methods of use thereof |
| 11/23/2005 | EP1597276A1 Therapeutic molecules |
| 11/23/2005 | EP1597275A2 Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof |
| 11/23/2005 | EP1597273A2 Soluble ctla4 polypeptides and methods for making the same |
| 11/23/2005 | EP1597271A2 Peptides directed against antibodies, which cause cold-intolerance, and the use thereof |
| 11/23/2005 | EP1597270A2 Peptidomimetic inhibitors of stat3 activity and their medical uses |
| 11/23/2005 | EP1597265A2 Glycosolated enkephalin agents |
| 11/23/2005 | EP1596884A2 Uses of integrin alphavbeta3 antagonists |
| 11/23/2005 | EP1596883A1 Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| 11/23/2005 | EP1596881A1 Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis |
| 11/23/2005 | EP1596880A2 Methods and compositions for suppressing fibrocyte differentiation |
| 11/23/2005 | EP1596879A1 Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |
| 11/23/2005 | EP1596878A2 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| 11/23/2005 | EP1596873A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 11/23/2005 | EP1596833A1 Particle formulation and its preparation |
| 11/23/2005 | EP1596828A2 Lipophilic drug delivery vehicle and methods of use thereof |
| 11/23/2005 | EP1596815A2 Composition and methods for inhibiting cell survival |
| 11/23/2005 | EP1596811A2 Compositions and methods to modulate immune and inflammatory responses |
| 11/23/2005 | EP1596804A2 SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF |
| 11/23/2005 | EP1546196A4 Marker for cancer |
| 11/23/2005 | EP1513558A4 METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1alpha |
| 11/23/2005 | EP1444347B1 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 11/23/2005 | EP1401495A4 T cell induced tissue repair and regeneration |
| 11/23/2005 | EP1390055B1 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 11/23/2005 | EP1381628B1 Inflammation-specific peptides and the uses thereof |
| 11/23/2005 | EP1287026B1 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| 11/23/2005 | EP1280777B1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 11/23/2005 | EP1276497B1 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors |
| 11/23/2005 | EP1250124B1 Slimming cosmetic composition comprising as active agent a plant extract containing a plant natriuretic peptide (pnp) |
| 11/23/2005 | EP1194161B1 Stable factor viii compositions |
| 11/23/2005 | EP1183034B1 Modulators of methylation for control of bacterial virulence |
| 11/23/2005 | EP1163528B1 Prediction of diabetes impaired wound healing |
| 11/23/2005 | EP1137401B1 Administration of neurotrophic agents to the central nervous system |
| 11/23/2005 | EP1133555B1 Pharmaceutical factor vii preparation |
| 11/23/2005 | EP1117383B1 Dosage form comprising therapeutic formulation |
| 11/23/2005 | EP1039930B1 ADJUVANTED VACCINE COMPRISING AN ANTIGEN FROM STREPTOCOCCUS PNEUMONIAE AND A CpG OLIGONUCLEOTIDE |
| 11/23/2005 | EP0958357B1 Novel method for testing the differentiation status in pancreatic cells of a mammal |
| 11/23/2005 | EP0939817B1 High-affinity interleukin-4 muteins |
| 11/23/2005 | EP0929311B1 INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| 11/23/2005 | EP0837939B1 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 11/23/2005 | EP0835305B1 Cytokine that induces apoptosis |
| 11/23/2005 | EP0781344B1 Novel implant and novel vector for the treatment of acquired diseases |
| 11/23/2005 | EP0770129B1 Zinc finger protein derivatives and methods therefor |
| 11/23/2005 | EP0732934B1 Long-acting injection suspensions of an lhrh analogue and a process for their preparation |
| 11/23/2005 | CN1701121A Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| 11/23/2005 | CN1701079A Genes and polypeptides relating to chronic myeloid leukemia |
| 11/23/2005 | CN1700930A Methods and reagents relating to inflammation and apoptosis |